Peter J. Dunbar

Peter J. Dunbar

Auto-generated profile, based on publicly available information

Peter J. Dunbar

Division of Pulmonary Sciences and Critical Care Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Academic Pediatrics
Verified
Journal Article
Closed access
AJAshley M. Jenkins
Ashley M. Jenkins
JBJay G. Berry
Jay G. Berry
JPJames M. Perrin
James M. Perrin
KKKaren Kuhlthau
Karen Kuhlthau
MHMatt Hall
Matt Hall
KAKatherine Auger
Katherine Auger

1 September 2025 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
PDPeter J. Dunbar
Peter J. Dunbar
RPRyan Peterson
Ryan Peterson
MMMax McGrath
Max McGrath
TKTyree H. Kiser
Tyree H. Kiser
PHP. Michael Ho
P. Michael Ho
PSPeter D. Sottile
Peter D. Sottile
Rationale: Neuromuscular blockade (NMB) is frequently used during acute respiratory distress syndrome (ARDS) to improve ventilator synchrony. Which sedating medications are used concomitantly during NMB and whether sedation choice influences patient outcomes are unclear. Objectives: To determine national sedation practice patterns during NMB in patients with and at risk for ARDS and to establish whether the use of propofol and opioids compared with benzodiazepines and opioids is associated with improved outcomes. Methods: Using a U.S. national database from 2010 to 2021, intubated and mechanically ventilated patients receiving NMB for a diagnosis of ARDS or an ARDS risk factor over at least two hospital days after admission were included. Charges for sedation and analgesia during the first two hospital days were recorded for each patient. The relationships between propofol and opioids and between benzodiazepines and opioids, with a primary outcome of ventilator-free days, as well as secondary outcomes of 28-day survival and discharge home were examined in multivariable analyses. Results: We determined that the use of propofol has increased compared with that of benzodiazepines as the primary sedative used during NMB for ARDS. Compared with benzodiazepine and opioid use, propofol and opioid use during NMB for ARDS was associated with increased ventilator-free days (adjusted odds ratio, 1.38 [95% confidence interval, 1.24–1.54]), greater odds for survival at 28 days (adjusted odds ratio, 1.15 [95% confidence interval, 1.01–1.31]), and greater odds for discharge home (adjusted odds ratio, 1.26 [95% confidence interval, 1.09–1.46]), adjusting for patient-level and hospital-level characteristics. Conclusions: From 2010 to 2021, sedation practice during NMB for ARDS shifted from predominately benzodiazepine use to predominately propofol use. The use of propofol and opioids is associated with an increase in ventilator-free days compared with the use of benzodiazepines and opioids. These results suggest that sedation choice during NMB for ARDS may affect clinical outcomes; further investigation is needed to validate these findings.

16 September 2022 in Academic Pediatrics
Verified
Journal Article
Closed access
PDPeter J. Dunbar
Peter J. Dunbar
SSSarah A. Sobotka
Sarah A. Sobotka
JRJonathan Rodean
Jonathan Rodean
CPChristian D. Pulcini
Christian D. Pulcini
MMMichelle L. Macy
Michelle L. Macy
JBJay G. Berry
Jay G. Berry

1 November 2018 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
RHRavi S. Hira
Ravi S. Hira
MRMichael Ring
Michael Ring
PDPeter Dunbar
Peter Dunbar
To the Editor In a Special Communication regarding the association of public reporting of percutaneous coronary intervention (PCI) outcomes with health care quality, Wadhera et al1 conclude that public reporting has not achieved its objectives and suggest potential solutions. We agree with disease-based reporting as a way to elucidate outcomes of variations in care. However, regarding other recommendations, public reporting in Washington is done differently compared with other states mentioned. We participate in a nonmandatory, physician-led reporting program with universal hospital participation and public accountability titled the Clinical Outcomes Assessment Program (COAP).2 The COAP began in 1999 as a statewide intervention to improve the quality of PCI and cardiac surgery. It is an autonomous, collaborative model of confidential clinical data sharing and peer education with a focus on quality improvement that is independent of governmental agencies. We publicly report several process and quality metrics, such as door-to-balloon time in patients with ST-elevation myocardial infarction, PCI appropriateness, radial artery use, postprocedure complications, length of stay, and unplanned coronary artery bypass grafting in addition to in-hospital mortality. These reports are at the hospital level, not the physician level, recognizing that quality and patient outcomes extend beyond the procedure itself.